Phase I single- and multiple-ascending dose trial of IMO 8400 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2014
At a glance
- Drugs IMO 8400 (Primary)
- Indications Psoriasis; Systemic lupus erythematosus
- Focus Adverse reactions; First in man; Pharmacodynamics
- 08 Dec 2014 According to an Idera Pharmaceuticals media release, clinical safety results of this and other trial (see profile 231094) were presented at 56th Annual Meeting of the American Society of Hematology .
- 07 Aug 2014 Results published in an Idera Pharmaceuticals media release.
- 30 Jun 2013 Positive results presented at the 3th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS), according to an Idera Pharmaceuticals media release.